Interestingly, the patent also seems to conceive of a mouse mode for a more traditional controller. While the design of the ...
The biggest stories of the day delivered to your inbox.
Novo Nordisk CFO Karsten Munk Knudsen says the company is trialing obesity medications for a new customer base. © 2024 Fortune Media IP Limited. All Rights Reserved ...
LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply improving this year, and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next-generation weight loss drugs ...
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO) is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...
To do so, Novo Nordisk’s CFO, Karsten Munk Knudsen, says the company is now looking at the next generation of weight loss drugs, which are expected to focus on specific subsets of the obese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback